vs. use with regional use with regional anesthesia anesthesia Only inhibits factor Only inhibits factor Xa Xa Bioavailability virtually 100%; can be given QD Bioavailability virtually 100%; can be given QD No thrombocytopenia seen in trials (does not No thrombocytopenia seen in trials (does not bind to platelet factor IV) bind to platelet factor IV) Data clearly shows it to be superior to LMWH Data clearly shows it to be superior to LMWH when given postoperatively, & probably superior when given postoperatively, & probably superior to LMWH given preoperatively to LMWH given preoperatively
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FONDAPARINUX FONDAPARINUX
Offers possibility of post Offers possibility of post--op prophylaxis op prophylaxis against DVT with same or better efficacy as against DVT with same or better efficacy as preop administration of LMWH preop administration of LMWH Small but real incidence of wound Small but real incidence of wound hematomas (nil if given > 6 hematomas (nil if given > 6 hrs hrs post post--op); op); bleeding risk otherwise similar to LMWH bleeding risk otherwise similar to LMWH Avoids problems with administration of drug Avoids problems with administration of drug during regional anesthesia, since can be during regional anesthesia, since can be given after the epidural catheter is pulled given after the epidural catheter is pulled Approved for treatment of VTE (7.5 mg QD) Approved for treatment of VTE (7.5 mg QD)
Prophylaxis vs TE Disease Prophylaxis vs TE Disease
Requires smaller dose than does Requires smaller dose than does treatment treatment Less risk of bleeding with prophylaxis Less risk of bleeding with prophylaxis doses doses Stratified by risk of developing Stratified by risk of developing thromboembolic disease thromboembolic disease In surgery patients, pre In surgery patients, pre--op therapy op therapy generally more effective than post generally more effective than post--op op therapy (with one exception) therapy (with one exception) 
